Resumo

RODRIGUEZ -JENKINS, Olger. Lamivudine. Acta méd. costarric [online]. 2008, vol.50, suppl.3, pp.49-50. ISSN 0001-6002.

lamivudine produces an intense inhibition of HBV replication and competitively blocks DNA-Polymerase activity. It is indicated in patients with chronic hepatitis B and with evidence of viral replication. It is administered orally with a single dose of 100 mg per day and a minimum recommended term of a year. It is well tolerated and long-term treatment is related to the appearance of resistant mutations that limit its benefit.

Palavras-chave : tratamiento; hepatitis B; lamivudina; treatment; hepatitis B; lamivudine.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )